Melanoma

NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021

Thursday, September 16, 2021 - 1:00pm

To that end, the preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort warrant attention.

Key Points: 
  • To that end, the preliminary disease control results observed with NGM120 in combination with gemcitabine/Nab-paclitaxel in the Phase 1b cohort warrant attention.
  • Patients are dosed once every three weeks in the Phase 1a cohort and once every four weeks in the Phase 1b cohort.
  • Overall, treatment with NGM120 showed no dose-limiting toxicities in the Phase 1a/1b study data presented at ESMO.
  • The PK exposure of NGM120 in both the Phase 1a and Phase 1b cohorts increased with dose.

Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma

Thursday, September 16, 2021 - 12:00pm

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced that it has received approval from the New York State Department of Health for its proprietary DecisionDx DiffDx-Melanoma gene expression profile (GEP) test.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced that it has received approval from the New York State Department of Health for its proprietary DecisionDx DiffDx-Melanoma gene expression profile (GEP) test.
  • DecisionDx DiffDx-Melanoma is designed to provide an objective and comprehensive diagnostic offering to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
  • Castle Biosciences comprehensive diagnostic offering leverages the strengths of myPath Melanoma and DecisionDx DiffDx-Melanoma.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress

Thursday, September 16, 2021 - 7:45am

The dataset is being presented in a poster titled MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.

Key Points: 
  • The dataset is being presented in a poster titled MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion (Poster #620P) at the 2021 European Society for Medical Oncology (ESMO) Virtual Conference taking place September 16-21, 2021.
  • As of the August 16, 2021 data cut-off, all 40 patients in the mCRPC cohort expansion had been enrolled.
  • As of the August 16, 2021 data cut-off, the NSCLC cohort expansion had been fully enrolled with 21 patients.
  • The safety analysis includes all 86 patients enrolled in the cohort expansion as of the August 16, 2021 data cut-off.

Targovax ASA: Poster at European Society for Medical Oncology (ESMO)

Thursday, September 16, 2021 - 6:42am

OSLO, Norway, Sept. 16, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the poster "A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma" is now available at the ESMO congress website and on the Company's website.  The poster will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.

Key Points: 
  • The poster will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.
  • The poster presents the pilot study of ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma.
  • The poster concludes that co-administration of ONCOS-102 and pembrolizumab is safe and feasible for patients with melanomas progressing on PD-1 blockade.
  • Rapid clinical objective responses were seen in patients treated both sequentially and in combination, and immune markers demonstrating induction of beneficial tumor microenvironment changes support the role of ONCOS-102 as a complementary treatment with aPD1 and other IO modalities.

Targovax ASA: Poster at European Society for Medical Oncology (ESMO)

Thursday, September 16, 2021 - 6:41am

The poster will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.

Key Points: 
  • The poster will be presented as an e-poster at the European Society for Medical Oncology (ESMO) congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center.
  • The poster presents the pilot study of ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma.
  • The poster concludes that co-administration of ONCOS-102 and pembrolizumab is safe and feasible for patients with melanomas progressing on PD-1 blockade.
  • Rapid clinical objective responses were seen in patients treated both sequentially and in combination, and immune markers demonstrating induction of beneficial tumor microenvironment changes support the role of ONCOS-102 as a complementary treatment with aPD1 and other IO modalities.

American Skin Association Announces New Board Member Eugene A. Bauer, MD

Wednesday, September 15, 2021 - 4:36pm

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.
  • He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company.
  • "We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors.
  • Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company.

T-Cure Bioscience Announces U.S. FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T Against Multiple Solid Tumors

Wednesday, September 15, 2021 - 8:00am

T-Cure acquired the KK-LC-1 TCR therapy under an exclusive, worldwide license with the National Cancer Institute (NCI) in 2020.

Key Points: 
  • T-Cure acquired the KK-LC-1 TCR therapy under an exclusive, worldwide license with the National Cancer Institute (NCI) in 2020.
  • The trial will be done under a Cooperative Research and Development Agreement (CRADA) that T-Cure has in place with the NCI.
  • TCR-T cell therapy is a promising new treatment modality that has demonstrated clinical activity in a subset of solid tumors.
  • We are excited that NCI has obtained the regulatory approval from FDA to initiate a first-in-human trial against a very important target in multiple solid tumors.

Immunolight, LLC Receives 200th Worldwide Patent

Tuesday, September 14, 2021 - 7:11pm

DURHAM, N.C., Sept. 14, 2021 /PRNewswire/ -- Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has been granted its 200th worldwide and 75th US patent in a wide-ranging patent portfolio.

Key Points: 
  • DURHAM, N.C., Sept. 14, 2021 /PRNewswire/ -- Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has been granted its 200th worldwide and 75th US patent in a wide-ranging patent portfolio.
  • The Immunolight patent estate continues to expand, with patents covering both the medical and non-medical commercial end-uses of the breakthrough Immunolight energy conversion technology.
  • An additional 117 worldwide patent applications are pending.
  • The current portfolio contains over 70 issued or allowed worldwide patents having claims specifically related to medical treatments.

Immunolight, LLC Receives 200th Worldwide Patent

Tuesday, September 14, 2021 - 7:11pm

DURHAM, N.C., Sept. 14, 2021 /PRNewswire/ -- Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has been granted its 200th worldwide and 75th US patent in a wide-ranging patent portfolio.

Key Points: 
  • DURHAM, N.C., Sept. 14, 2021 /PRNewswire/ -- Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has been granted its 200th worldwide and 75th US patent in a wide-ranging patent portfolio.
  • The Immunolight patent estate continues to expand, with patents covering both the medical and non-medical commercial end-uses of the breakthrough Immunolight energy conversion technology.
  • An additional 117 worldwide patent applications are pending.
  • The current portfolio contains over 70 issued or allowed worldwide patents having claims specifically related to medical treatments.

Oncology Pipeline Database 2021: Indication; Clinical Trial Stages; Drug Mechanism Classes; Competitive Landscape - ResearchAndMarkets.com

Tuesday, September 14, 2021 - 2:18pm

Oncology Pipeline Highlights Database - 2021, provides the most up-to-date information on key pipeline products in the global Oncology Drug market.

Key Points: 
  • Oncology Pipeline Highlights Database - 2021, provides the most up-to-date information on key pipeline products in the global Oncology Drug market.
  • It covers emerging therapies for Oncology indications in active clinical development stages including early and late-stage clinical trials.
  • Key indications covered in this database include Esophageal Cancer Stomach Cancer, Colon Cancer, Pancreatic Cancer, Malignant Melanoma, Breast Cancer, Cervical Cancer, Ovary Cancer, Prostate Cancer, Renal Cancer, Bladder Cancer, Brain Cancer, Hodgkin's disease, Acute Myeloid Leukemia and Multiple Myeloma.
  • The database provides Oncology pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.